<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908685</url>
  </required_header>
  <id_info>
    <org_study_id>BP39055</org_study_id>
    <secondary_id>2016-000750-35</secondary_id>
    <nct_id>NCT02908685</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants</brief_title>
  <acronym>SUNFISH</acronym>
  <official_title>A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      Multi-center, randomized, double-blind, placebo-controlled study to assess the safety,
      tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and
      pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an
      exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part
      (Part 2) of Risdiplam for 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Anticipated">September 2, 2023</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 2: Change from Baseline in the Total Motor Function Measure 32 (MFM-32) Score at Month 12</measure>
    <time_frame>Baseline (Day -1) and Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Recommended Part 2 Dose of Risdiplam</measure>
    <time_frame>Minimum of 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron 2 (SMN2) Messenger Ribonucleic Acid (mRNA) Levels in Blood</measure>
    <time_frame>Part 2: Days -1, 1, 7, 28, 120, 246, 365, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of Motor Neuron (SMN) Protein Levels in Blood</measure>
    <time_frame>Part 2: Days -1, 7, 28, 120, 246, 365, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Score of Hammersmith Functional Motor Scale Expanded (HFMSE) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Total Score of the Revised Upper Limb Module (RULM) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Stabilization or Improvement (Defined as &gt;= 0) in the Total Motor Function Measure (MFM) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Best Sniff Nasal Inspiratory Pressure (SNIP) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Forced Vital Capacity (FVC) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Peak Cough Flow (PCF) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Maximal Inspiratory Pressure (MIP) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Maximal Expiratory Pressure (MEP) at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Experience at Least One Disease-Related Adverse Event</measure>
    <time_frame>Baseline up to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Maximum Plasma Concentration (Cmax) of Risdiplam</measure>
    <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (Part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (Part 1), 365, 609</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Area Under the Curve (AUC) of Risdiplam</measure>
    <time_frame>Part 1 and 2: 1, 2, 4, 6 hours post dose on Day 1; Pre-dose (Hour 0) on Days 7, 14, 56 (Part 2), 120, 246, 490, 729; pre-dose (Hour 0) and 1, 2, 4, 6 hours post dose on Days 28, 56 (Part 1), 365, 609</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Concentration at the End of a Dosing Interval (Ctrough) of Risdiplam</measure>
    <time_frame>Part 1 and 2: Pre-dose (Hour 0) on Days 7, 14, 28, 56, 120, 246, 365, 490, 609, 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the MFM Domain 1 (D1) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the MFM Domain 2 (D2) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the MFM Domain 3 (D3) Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Total Combined Scores of MFM Domains 1 and 2 at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suicidal Ideation or Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score</measure>
    <time_frame>Baseline (Day-1), Day 120, Day 248, Day 386, Day 647, Day 729</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Clinical Global Impression of Change (CGI-C) Scale Ratings</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SMA Independence Scale (SMAIS) Total Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve an Improvement of at Least One Standard Error of Measurement on the Total MFM Score at Month 12</measure>
    <time_frame>Baseline (Day-1) and Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Muscular Atrophy, Spinal</condition>
  <arm_group>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Risdiplam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescent and adult participants aged 12-25 years will receive risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in open-label extension (OLE) phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adolescent and adult participants aged 12-25 years will receive placebo matching to risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Children aged 2-11 years will receive placebo matching to risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group B: Children (Risdiplam)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children aged 2-11 years will receive risdiplam for 12 weeks. Once 12-week treatment is completed and Part 2 dose is selected, participants will be switched to Part 2 dose and will be followed up in OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 2-25 years will receive placebo matching to risdiplam. After 12 months of treatment with placebo, participants will be switched to risdiplam and treatment will then continue until Month 24. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Risdiplam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2-25 years will receive risdiplam at the dose selected based on the results from Part 1 of the study, for 24 months. After 24-month treatment, participants will be offered the opportunity to enter the OLE phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).</description>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risdiplam</intervention_name>
    <description>Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).</description>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group A: Adolescents and Adults (Risdiplam)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Placebo)</arm_group_label>
    <arm_group_label>Part 1 Group B: Children (Risdiplam)</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_label>Part 2: Risdiplam</arm_group_label>
    <other_name>RO7034067</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of 5q-autosomal recessive SMA

          -  Negative blood pregnancy test at screening and agreement to comply with measures to
             prevent pregnancy and restrictions on sperm donation

          -  For Part 1: Type 2 or 3 SMA ambulant or non-ambulant

          -  For Part 2: 1) Type 2 or 3 SMA non-ambulant; 2) RULM entry item A greater than or
             equal to 2; 3) ability to sit independently as assessed by item 9 of the MFM

        Exclusion Criteria:

          -  Concomitant or previous participation in any investigational drug or device study
             within 90 days prior to screening, or 5 half-lives of the drug, whichever is longer

          -  Concomitant or previous administration of a SMN2-targeting antisense oligonucleotide,
             SMN2 splicing modifier or gene therapy either in a clinical study or as part of
             medical care

          -  Any history of cell therapy

          -  Hospitalization for a pulmonary event within the last 2 months or planned at time of
             screening

          -  Surgery for scoliosis or hip fixation in the one year preceding screening or planned
             within the next 18 months

          -  Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system
             diseases as considered to be clinically significant by the Investigator

          -  Presence of clinically significant electrocardiogram abnormalities before study drug
             administration from average of triplicate measurement or cardiovascular disease
             indicating a safety risk for participants as determined by the Investigator

          -  Any major illness within one month before the screening examination or any febrile
             illness within one week prior to screening and up to first dose administration

          -  Recently initiated treatment (within less than [&lt;] 6 months prior to randomization)
             with oral salbutamol or another beta 2-adrenergic agonist taken orally

          -  Any prior use of chloroquine, hydroxychloroquine, retigabin, vigabatrin or
             thioridazine, is not allowed

          -  Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to Risdiplam
             or to the constituents of its formulation

          -  Recent history (less than one year) of ophthalmological diseases

          -  Participants requiring invasive ventilation or tracheostomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; The Neurological Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chr de La Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura E Pediatria Martagão Gesteira</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>CEP 21941-912</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital Division of Pediatric Neurology</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre; Children's Hospital; Pediatrics</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing City</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Center Zagreb; University Hospital Rebro Department of Paediatrics</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique - L'ESCALE</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades; Service de neuropédiatrie</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico &quot;Carlo Besta&quot;; UO di Neurologia dello Sviluppo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minami Kyushu National Hospital</name>
      <address>
        <city>Kagoshima</city>
        <zip>899-5293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Children's Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>989-3126</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiga Medical Center for Children</name>
      <address>
        <city>Shiga</city>
        <zip>524-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Children's Hospital</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospital of the National Center for Global Health and Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>162-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center Of Neurology And Psychiatry Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. H. Swiecickiego U.M. w Poznaniu; Od. Kliniczny Neurologii Dzieci i Młodziezy</name>
      <address>
        <city>Poznań</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Children Neuromuscular Center of Veltischev</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology and Psychiatry for Children and Youth</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu</name>
      <address>
        <city>Esplugues De Llobregas</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Reumatologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>280146</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío; Servicio de Neuropediatra</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University, School of Medicine; Pediatrics Department; Pediatrics Child Neurology Unit</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://roche-sma-clinicaltrials.com</url>
    <description>roche-sma-clinicaltrials.com provides information about the Roche Sunfish clinical trial NCT02908685 and molecule being investigated in SMA.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risdiplam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

